PACT Pharma to Present New Data Highlighting First-of-its-Kind Personalized Neoantigen TCR T Cell Therapy Platform at SITC 2022

Oral and Poster Presentations Highlight Feasibility of Creating, Manufacturing, and Administering Non-Viral Precision Genome Engineered Tumor Specific T Cell Therapies for Solid Tumors

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T cell therapies for the eradication of solid tumors, today announced that new data highlighting its first-of-its-kind adoptive T cell therapy platform will be featured in multiple presentations at the upcoming 37^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022). The company, along with academic research collaborators, will deliver oral and poster presentations, including a late-breaking oral presentation, providing the latest clinical and preclinical findings from its pioneering research in the field of personalized neoantigen TCR T cell therapies. SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.

Details of the company's presentations at SITC 2022 are as follows:

Late Breaking Oral Presentation #1478 (With Accompanying Poster):

• Title: A Phase I Study of Personalized Adoptive TCR T Cell Therapy in Patients with Solid Tumors: Safety, Efficacy, and T Cell Trafficking to Tumors of Non-virally Gene Edited T Cells
• Presenting Author: Stefanie Mandl, Ph.D., chief scientific officer, PACT Pharma
• Category/Session: Late Breaking Abstract Session 103
• Date/Time: Thursday, November 10, 2022, 11:10 a.m. – 11:40 a.m. Eastern
• Location: Hall B2

Oral Presentation #123:

• Title: Landscape Analysis of the Neoepitope-specific T Cell Responses in Patients with and without Clinical Benefit from Immune Checkpoint Blockade Therapy
• Presenting Author: Cristina Puig Saus, Ph.D., adjunct assistant professor, University of California, Los Angeles
• Category/Session: Rapid Oral Abstracts – Basic Science Session 104
• Date/Time: Thursday, November 10, 2022, 12:25 – 12:33 p.m. Eastern
• Location: 253ABC

Poster Presentation #320:

• Title: Rapid Identification of a TCR Library Targeting the HPV E6/E7 Oncoproteins to Enable Multi-TCR T-Cell Therapies for Patients with HPV16+ Epithelial Cancers
• Presenting Author: Stefanie Mandl, Ph.D., chief scientific officer, PACT Pharma
• Category/Session: Cellular Therapies Poster Session
• Date: Friday, November 11, 2022
• Location: Poster Hall C

Poster Presentation #712:

• Title: Retrospective Tumor Microenvironment Analysis from a Personalized neoTCR-T Cell Therapy Clinical Trial and Its Potential Applications for Off-the-Shelf HPV TCR T Cell therapies
• Presenting Author: Chad Smith, Ph.D., associate director, bioinformatics, PACT Pharma
• Category/Session: Clinical Trials in Progress Poster Session
• Date: Friday, November 11, 2022
• Location: Poster Hall C

Additional information on the 37^th Annual Meeting of SITC is available through the conference website at: https://www.sitcancer.org/2022/home

PACT is a privately held biopharmaceutical company pioneering individualized and off-the-shelf, non-viral precision genome engineered, tumor-specific TCR T cell therapies for the treatment of patients with solid cancers.

For more information, please visit www.pactpharma.com.

Contacts:

PACT Pharma
Atulya R. Agarwal
aagarwal@pactpharma.com

Vida Strategic Partners (on behalf of PACT Pharma)
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pact-pharma-to-present-new-data-highlighting-first-of-its-kind-personalized-neoantigen-tcr-t-cell-therapy-platform-at-sitc-2022-301665733.html

SOURCE PACT Pharma